SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation

The RET receptor tyrosine kinase proto-oncogene is activated by somatic or germline mutations in a majority of medullary thyroid cancers (MTC). However, treatment of MTC has been challenging due to the lack of effective and tolerable RET-specific therapy, thus testing tumors for the presence of soma...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabanillas, Maria E, Wirth, Lori J, Sherman, Eric J, Drilon, Alexander, Solomon, Benjamin, Robinson, Bruce G, Lorch, Jochen H, McCoach, Caroline, Patel, Jyoti, Leboulleux, Sophie, Worden, Francis, Owonikoko, Taofeek K, Brose, Marcia S, Taylor, Matthew H, Subbiah, Vivek, Rothenberg, S Michael, Huang, Xin, Zhu, Edward, French, Pearl P, Shah, Manisha H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Thyroid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208240/
http://dx.doi.org/10.1210/jendso/bvaa046.2223

Ejemplares similares

Ejemplares similares